Scholar Rock resubmits EMA filing: what it means for Scholar Rock stock

Published on 10/18/2026 at 13:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EMA filing targets a CHMP opinion in the first half of 2027. Scholar Rock stock had USD 492 million cash and a USD 109.9 million net loss in Q2 2026.

Regulatory path and financial runway

Scholar Rock resubmitted its European application on October 8, 2026.
Second-quarter cash reached USD 492.0 million against a USD 109.9 million GAAP net loss.
Third-quarter results are estimated for November 13, 2026.

SRRK, US80706P1030, Illustration mit AI erstellt.

Scholar Rock (ISIN US80706P1030) resubmitted its apitegromab marketing application to the European Medicines Agency on October 8, 2026, according to Scholar Rock. The filing replaces the Catalent Indiana fill-finish facility with an alternate site and sets up a possible European regulatory opinion in the first half of 2027.

Three regulatory steps shaped the story

On September 11, 2026, the U.S. Food and Drug Administration approved ISEMBYLD, the company's apitegromab product, for adults and children aged 2 and older with spinal muscular atrophy, according to Scholar Rock. On September 21, 2026, the company granted inducement awards covering 83,102 shares to 10 newly hired employees, according to Scholar Rock.

The October 8 filing was the latest of the three events. Scholar Rock said the alternate facility had supported the U.S. approval and that vials were awaiting packaging and labeling, making manufacturing readiness the key European execution point.

What does the filing mean for timing?

The company anticipates a Committee for Medicinal Products for Human Use opinion in the first half of 2027. That timing gives investors a defined regulatory milestone after the earlier withdrawal linked to manufacturing compliance at the Catalent facility.

Financial capacity remains a second marker. Scholar Rock ended the second quarter of 2026 with USD 492.0 million in cash, cash equivalents and marketable securities, while operating expenses reached USD 108.9 million, including USD 19.7 million in non-cash stock-based compensation, according to Benzinga. GAAP net loss was USD 109.9 million for the quarter ended June 30, 2026.

Dates that frame the next phase

MarketBeat estimates November 13, 2026 for Scholar Rock's third-quarter results. The company also points to the first half of 2027 for the European regulatory opinion.

Europe adds a second catalyst

The last available euro price stood at EUR 37.64 on Tradegate on October 12, 2026. The regulatory filing connects the European opportunity with a manufacturing solution, while the balance sheet provides USD 492.0 million for the launch phase.

The further course of trading is shown by the continuously updated real-time quote of SRRK stock.